Faes Farma : Investor day highlights: discouraging message on Hikma’s attempt to register Bilastine in US
>FY23 likely to be a transition year with limited (if any) earnings growth - FY22 was a record year in terms of earnings, but total shareholder return was modest at best (+2%). The year was marked by the patent expiration in Europe of its key product Bilastine (25% of group sales) and weak trends for its animal health unit (14% of group sales), impacted by cost inflation and swine flu (Europe’s pig population fell -5% in 2022), factors that were offset by market expan...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.